Piegols Hunter J, Williams Rachel W, Pathak Nirali, Selmic Laura E, Tremolada Giovanni, Sakacs Russell, Millward Laurie, Lapsley Janis
The Ohio State University Veterinary Medical Center, The Ohio State University, Columbus, Ohio, USA.
UF Small Animal Hospital, University of Florida, Gainesville, Florida, USA.
J Vet Intern Med. 2025 May-Jun;39(3):e70021. doi: 10.1111/jvim.70021.
The utility of cytologic evaluation to distinguish adrenocortical tumors and pheochromocytomas in dogs has not been thoroughly investigated, partly because of the perceived risks of the procedure.
Report test characteristics of fine needle aspiration (FNA) and cytologic evaluation for differentiation of adrenocortical tumors and pheochromocytomas in dogs. Complications associated with FNA also were recorded.
Thirty-eight dogs with 40 adrenal tumors that had FNA and cytologic evaluation performed before adrenalectomy were included in the study from three institutions. Tumors included 17 pheochromocytomas, 21 adrenocortical tumors, 1 concurrent adrenocortical adenoma and pheochromocytoma, and 1 malignant neoplasm.
Of the 40 FNA cytologic aspirations performed, 35 (87.5%) had a predominant cell type identified and therefore were considered of diagnostic quality. Of these, 30 (85.7%) correlated with the final histopathological diagnosis. When all samples were included, FNA and cytologic evaluation had a sensitivity of 77.3%, specificity of 76.5%, positive predictive value of 81.0%, negative predictive value of 72.2%, and accuracy of 76.9% for identifying adrenocortical tumors. For pheochromocytomas, these values were 72.2%, 95.2%, 92.8%, 80.0%, and 84.5%, respectively. Six (15.9%) dogs had self-limiting complications associated with the FNA procedure.
Fine needle aspiration and cytologic evaluation of adrenal tumors has a low complication rate and can help differentiate adrenocortical tumors and pheochromocytomas. Thus, cytologic evaluation of adrenal tumors should be considered to help differentiate adrenal tumors and allow more individualized treatment of affected dogs.
细胞学评估在区分犬肾上腺皮质肿瘤和嗜铬细胞瘤方面的实用性尚未得到充分研究，部分原因是该操作存在一定风险。
报告细针穿刺抽吸（FNA）及细胞学评估在区分犬肾上腺皮质肿瘤和嗜铬细胞瘤方面的检测特征。同时记录与FNA相关的并发症。
来自三个机构的38只患有40个肾上腺肿瘤的犬被纳入研究，这些犬在肾上腺切除术前均接受了FNA及细胞学评估。肿瘤包括17个嗜铬细胞瘤、21个肾上腺皮质肿瘤、1个同时存在的肾上腺皮质腺瘤和嗜铬细胞瘤以及1个恶性肿瘤。
在进行的40次FNA细胞学抽吸中，35次（87.5%）确定了主要细胞类型，因此被认为具有诊断价值。其中，30次（85.7%）与最终的组织病理学诊断相符。当纳入所有样本时，FNA及细胞学评估在识别肾上腺皮质肿瘤方面的敏感性为77.3%，特异性为76.5%，阳性预测值为81.0%，阴性预测值为72.2%，准确性为76.9%。对于嗜铬细胞瘤，这些值分别为72.2%、95.2%、92.8%、80.0%和84.5%。6只（15.9%）犬出现了与FNA操作相关的自限性并发症。
肾上腺肿瘤的细针穿刺抽吸及细胞学评估并发症发生率低，有助于区分肾上腺皮质肿瘤和嗜铬细胞瘤。因此，应考虑对肾上腺肿瘤进行细胞学评估，以帮助区分肾上腺肿瘤，并为患病犬提供更个体化的治疗。
